Department of Medicine, New York University School of Medicine, New York, New York, USA.
Anal Chem. 2012 Oct 2;84(19):8106-9. doi: 10.1021/ac302136e. Epub 2012 Sep 18.
The use of gadolinium-based contrast agents (GBCA) is integral to the field of diagnostic magnetic resonance imaging (MRI). Pharmacokinetic evaluation of the plasma clearance of GBCA is required for all new agents or improved formulations, to address concerns over toxicity or unforeseen side effects. Current methods to measure GBCA in plasma lack either a rapid readout or the sensitivity to measure small samples or require extensive processing of plasma, all obstacles in the development and characterization of new GBCA. Here, we quantify the plasma concentration of a labeled analogue of a common clinical GBCA by ligand triplet harvesting and energy transfer. The nonemittive GBCA becomes a "dark donor" to a fluorescent detector molecule, with a lower limit of detection of 10(-7) M in unprocessed plasma. On a time scale of minutes, we determine the plasma clearance rate in the wild-type mouse, using time-resolved fluorescence on a standard laboratory plate reader.
钆基造影剂(GBCA)的使用是诊断磁共振成像(MRI)领域不可或缺的一部分。对于所有新的造影剂或改良制剂,都需要对其血浆清除率进行药代动力学评估,以解决毒性或意外副作用方面的担忧。目前用于测量血浆中 GBCA 的方法要么缺乏快速读数,要么灵敏度不足以测量小样本,要么需要对血浆进行大量处理,这些都是新 GBCA 开发和表征的障碍。在这里,我们通过配体三重态俘获和能量转移来定量分析一种常见临床 GBCA 的标记类似物的血浆浓度。非发光 GBCA 成为荧光检测分子的“暗供体”,在未经处理的血浆中的检测下限为 10(-7) M。在标准实验室平板读数器上进行时间分辨荧光,我们在几分钟的时间内确定了野生型小鼠的血浆清除率。